Daiichi Sankyo teams up with US firm to develop biosimilars Mainichi Daily News Daiichi Sankyo will introduce relevant technology from Coherus BioSciences to develop biosimilar forms of etanercept for rheumatism treatment and rituximab for cancer treatment. The Japanese drugmaker will put them on sale in Japan, South Korea and ... Daiichi Sankyo, Coherus partner to develop biosimilar candidates Coherus launches with Daiichi Sankyo biosimilar pact |
